It is important to note that the panel testing also highlights patients who should not receive treatment due to the presence of confounding activating mutations, in particular, CRC patients with activating mutations in KRAS or NRAS, for whom treatment with anti-EGFR monoclonal antibody is not indicated, and GIST patients with activating mutations in KIT or PDGFRA, who are not eligible for imatinib. Here, NRAS is linked to gastrointestinal stromal tumor.